Filtered By:
Cancer: Glioma
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells
This study aimed to understand the potential role and molecular mechanism of the combination therapy of B7H6-siRNA and temozolomide in glioblastoma cancer. U87 cells were treated with B7H6-siRNA and temozolomide, separately and in combination. Cell viability, stemness, cell migration, and apoptosis were measured. The results of this work presented the synergistic effect of B7H6-siRNA and temozolomide in inhibiting the cancerous features of the U87 cell line. Down-regulating B7H6-siRNA expression inhibited the cell viability of U87 glioblastoma cancer cells and increased their sensitivity to temozolomide. In addition, a not...
Source: Experimental Cell Research - May 29, 2023 Category: Cytology Authors: Nadia Allahyarzadeh Khiabani Mohammad Amin Doustvandi Fateme Mohammadnejad Elnaz Salmani Hassan Kohal Neda Boushehri Mahdi Jafarlou Behzad Baradaran Source Type: research
Intelligent Nanoparticles With pH-Sensitive Co-Delivery of Temozolomide and siEGFR to Ameliorate Glioma Therapy
In this study, pH-sensitive and GBM-targeting nanovesicle (Tf-PEG-PAE(SS)) was fabricated. The chemotherapy drug (TMZ) and EGFR inhibitor (EGFR-siRNA) were co-encapsulated in the nanocarrier, and their anticancer outcomes were investigated in detail. In vitro experiments have shown that the nanocarrier transports TMZ and EGFR-siRNA efficiently into U87 cells, causing a vigorous apoptotic response by silencing the proliferative EGFR gene and increasing the drug concentration of TMZ simultaneously. An experimental study in mice bearing orthotropic glioma revealed that the accumulated nanocarriers in the tumor site could inhi...
Source: Frontiers in Genetics - July 12, 2022 Category: Genetics & Stem Cells Source Type: research
HOXC6 Regulates the Epithelial-Mesenchymal Transition through the TGF- < em > β < /em > /Smad Signaling Pathway and Predicts a Poor Prognosis in Glioblastoma
CONCLUSIONS: HOXC6 enhances the migration and proliferation of GBM by activating the EMT signaling pathway.PMID:35571491 | PMC:PMC9098331 | DOI:10.1155/2022/8016102
Source: Journal of Oncology - May 16, 2022 Category: Cancer & Oncology Authors: Sun Eryi Li Zheng Cai Honghua Zhao Su Xie Han Pan Donggang Zhou Zhou Zhan Liping Chen Bo Source Type: research
EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
Biomed Pharmacother. 2021 Dec 11;146:112532. doi: 10.1016/j.biopha.2021.112532. Online ahead of print.ABSTRACTBrain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. The present review focuses on EZH2 signaling in brain tumors including glioma, gliobla...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 15, 2021 Category: Drugs & Pharmacology Authors: Mahshid Deldar Abad Paskeh Atefeh Mehrabi Mohammad Hossein Gholami Amirhossein Zabolian Ehsan Ranjbar Hossein Saleki Adnan Ranjbar Mehrdad Hashemi Yavuz Nuri Ertas Kiavash Hushmandi Sepideh Mirzaei Milad Ashrafizadeh Ali Zarrabi Saeed Samarghandian Source Type: research
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death
Cell Tissue Res. 2021 Jul 8. doi: 10.1007/s00441-021-03481-0. Online ahead of print.ABSTRACTGliomas are aggressive brain tumors with very high resistance to chemotherapy throughout the overexpression of multiple intracellular survival pathways. Therefore, the aim of the present study was to investigate for the first time the anticancer activity of LY294002, phosphatidylinositol 3-kinase (PI3K) inhibitor and sorafenib, and rapidly accelerated fibrosarcoma kinase (Raf) inhibitor in the elimination of human glioma cells by programmed cell death. MOGGCCM (anaplastic astrocytoma, III) and T98G (glioblastoma multiforme, IV) cell...
Source: Cell Research - July 8, 2021 Category: Cytology Authors: Zaj ąc A Sumorek-Wiadro J Maciejczyk A Langner E Wertel I Rzeski W Jakubowicz-Gil J Source Type: research
Regulation of temozolomide resistance in glioma cells via the RIP2/NF- κB/MGMT pathway.
CONCLUSION: We report that the RIP2/NF-κB/MGMT signaling pathway is involved in the regulation of TMZ resistance. Interference with NF-κB or MGMT activity could constitute a novel strategy for the treatment of RIP2-positive TMZ-resistant glioma.
PMID: 33460245 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - January 18, 2021 Category: Neuroscience Authors: Hu YH, Jiao BH, Wang CY, Wu JL Tags: CNS Neurosci Ther Source Type: research
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model
AbstractGlioblastoma is the most devastating primary brain tumor and effective therapies are not available. Treatment is based on surgery followed by radio and chemotherapy with temozolomide (TMZ), but TMZ increases patient survival only by 2 months. CD73, an enzyme responsible for adenosine production, emerges as a target for glioblastoma treatment. Indeed, adenosine causes tumor-promoting actions and CD73 inhibition increases sensitivity to TMZ in vitro. Here, a cationic nanoemulsion to nasal delivery of siRNA CD73 (NE-siRNA CD73) ai ming glioblastoma treatment was employed alone or in combination with TMZ. In vitro, t...
Source: Cancer Chemotherapy and Pharmacology - May 15, 2020 Category: Cancer & Oncology Source Type: research
G3BP1 knockdown sensitizes U87 glioblastoma cell line to Bortezomib by inhibiting stress granules assembly and potentializing apoptosis
ConclusionOur data suggest G3BP1 knockdown diminishes SG formation and stimulates BZM-induced apoptosis of U87 cells in vitro, in addition to inhibiting glioblastoma-induced angiogenesis in vivo.
Source: Journal of Neuro-Oncology - August 6, 2019 Category: Cancer & Oncology Source Type: research
Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway
ConclusionsTaken together, the results of our study demonstrate that celastrol sensitizes glioma cells to TRAIL via the death receptor pathway and that DR5 plays an important role in the effects of this cotreatment. The results indicate that this cotreatment is a promising tumor-killing therapeutic strategy with high efficacy and low toxicity.
Source: Cancer Chemotherapy and Pharmacology - July 7, 2019 Category: Cancer & Oncology Source Type: research
Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4*
1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States
2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States
3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research
